MediciNova (MNOV) Competitors $1.32 +0.02 (+1.92%) As of 06/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNOV vs. PVLA, CADL, CRDF, INZY, IMMP, LFCR, FHTX, AARD, NBTX, and TVRDShould you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Palvella Therapeutics (PVLA), Candel Therapeutics (CADL), Cardiff Oncology (CRDF), Inozyme Pharma (INZY), Immutep (IMMP), Lifecore Biomedical (LFCR), Foghorn Therapeutics (FHTX), Aardvark Therapeutics (AARD), Nanobiotix (NBTX), and Cara Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. MediciNova vs. Its Competitors Palvella Therapeutics Candel Therapeutics Cardiff Oncology Inozyme Pharma Immutep Lifecore Biomedical Foghorn Therapeutics Aardvark Therapeutics Nanobiotix Cara Therapeutics Palvella Therapeutics (NASDAQ:PVLA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment. Which has more volatility & risk, PVLA or MNOV? Palvella Therapeutics has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Is PVLA or MNOV more profitable? MediciNova's return on equity of -20.77% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -60.29% -43.30% MediciNova N/A -20.77%-19.68% Which has higher earnings and valuation, PVLA or MNOV? MediciNova has lower revenue, but higher earnings than Palvella Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M5.70-$17.43M-$12.10-1.82MediciNova$1M65.24-$11.04M-$0.23-5.78 Do institutionals and insiders believe in PVLA or MNOV? 40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by insiders. Comparatively, 13.6% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer PVLA or MNOV? In the previous week, Palvella Therapeutics had 5 more articles in the media than MediciNova. MarketBeat recorded 7 mentions for Palvella Therapeutics and 2 mentions for MediciNova. MediciNova's average media sentiment score of 0.93 beat Palvella Therapeutics' score of 0.43 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PVLA or MNOV? Palvella Therapeutics currently has a consensus price target of $46.29, suggesting a potential upside of 109.63%. MediciNova has a consensus price target of $7.00, suggesting a potential upside of 426.32%. Given MediciNova's stronger consensus rating and higher possible upside, analysts clearly believe MediciNova is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13MediciNova 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryMediciNova beats Palvella Therapeutics on 9 of the 15 factors compared between the two stocks. Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNOV vs. The Competition Export to ExcelMetricMediciNovaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.76M$2.84B$5.48B$8.87BDividend YieldN/A2.70%5.35%4.15%P/E Ratio-5.7821.1626.2319.66Price / Sales65.24282.55386.95105.10Price / CashN/A43.1436.4056.81Price / Book1.247.207.905.44Net Income-$11.04M-$55.15M$3.16B$249.37M7 Day Performance3.10%0.76%3.09%3.98%1 Month Performance-6.34%6.31%6.03%5.29%1 Year Performance-7.64%-0.21%32.07%17.08% MediciNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNOVMediciNova1.9576 of 5 stars$1.33+2.3%$7.00+426.3%-7.6%$63.76M$1M-5.7810PVLAPalvella Therapeutics3.2457 of 5 stars$23.42-6.5%$46.29+97.6%N/A$258.93M$42.81M-1.94N/ACADLCandel Therapeutics1.8981 of 5 stars$5.16+0.6%$21.00+307.0%-16.8%$258.53M$120K-2.9860News CoveragePositive NewsCRDFCardiff Oncology1.6519 of 5 stars$3.86+1.3%$12.00+210.9%+35.2%$256.79M$587K-4.1120News CoverageAnalyst ForecastINZYInozyme Pharma3.4244 of 5 stars$3.97-0.5%$11.75+196.0%-11.7%$256.31MN/A-2.5450IMMPImmutep1.4228 of 5 stars$1.71-1.7%$7.00+309.4%-12.3%$249.73M$5.14M0.002,021Positive NewsLFCRLifecore Biomedical1.5808 of 5 stars$6.67-0.9%$8.00+19.9%+59.3%$246.96M$130.31M-11.91690FHTXFoghorn Therapeutics1.979 of 5 stars$4.39+1.6%$12.13+176.2%-15.7%$244.70M$23.50M-2.29120Positive NewsAARDAardvark TherapeuticsN/A$10.85+1.0%$31.25+188.0%N/A$235.40MN/A0.0018Gap UpNBTXNanobiotix2.4165 of 5 stars$4.99-6.6%$8.00+60.5%-17.7%$234.96M-$11.61M0.00100Positive NewsTVRDCara TherapeuticsN/A$24.96+1.4%$71.50+186.5%N/A$233.65MN/A0.0080News Coverage Related Companies and Tools Related Companies PVLA Competitors CADL Competitors CRDF Competitors INZY Competitors IMMP Competitors LFCR Competitors FHTX Competitors AARD Competitors NBTX Competitors TVRD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNOV) was last updated on 6/28/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MNOV Stock Free MNOV Stock Alerts